Background: Cervical cancer is the 2nd most common in India. It cause of death developing countries. According to current global status 2016, age-standardized incidence rate cervical varies between 5.6 24.3 per 1 lakh women Human papillomavirus (HPV) responsible for subclinical/clinical lesions cancer. occurs early and strikes at productive period a woman’s life. The vaccines against HPV are bi...

Human papillomavirus (HPV) is a well-known sexually transmitted disorder globally. the 3rd most common cancer that causes cervical carcinoma, and globally it accounts for 275,000 deaths every year. The load of HPV-associated abrasions can be lessened through vaccination. At present, three forms prophylactic vaccines, Cervarix, Gadrasil, Gardasil 9, are commercially accessible but all these vacc...

This issue of the Journal presents the results of an experimental project describing the technology and the model system to generate novel human papillomavirus (HPV) vaccines. Rather than using the immune capacity of the L1 capsid epitopes, these prototypes are based on the unique properties of the L2 protein of the capsid to induce broad-spectrum (BS) HPV antigenic recognition and the formatio...

BACKGROUND Previous analyses from a randomized trial in women aged 24-45 have shown the quadrivalent HPV vaccine to be efficacious in the prevention of infection, cervical intraepithelial neoplasia (CIN) and external genital lesions (EGL) related to HPV 6/11/16/18 through 4 years. In this report we present long term follow-up data on the efficacy, safety and immunogenicity of the quadrivalent H...

We report the case of a 14-year-old girl who developed postural orthostatic tachycardia syndrome (POTS) with chronic fatigue 2 months following Gardasil vaccination. The patient suffered from persistent headaches, dizziness, recurrent syncope, poor motor coordination, weakness, fatigue, myalgias, numbness, tachycardia, dyspnea, visual disturbances, phonophobia, cognitive impairment, insomnia, g...

To the Editor: We are grateful to Griffith et al. for the opportunity to clarify this point. We intended to convey that the partners of patients with human papillomavirus (HPV)16-positive oropharyngeal cancer would be unlikely to benefit from prophylactic vaccination to prevent infection with HPV16, as they are likely to already have been exposed to this HPV type. Because both Cervarix and Gard...

Vaccination policy in the case of human papillomavirus (HPV) has remained a constant source of controversy ever since Gardasil, Merck's vaccine against HPV, received US Food and Drug Administration approval in the summer of 2006. This controversy has centered on the risks and benefits of vaccinating girls and women in rich and poor nations alike. However, despite all of the attention created by...

15 The development of not one, but two vaccines against human papillomavirus (HPV), which have been shown to be highly effective in preventing infections that cause at least 70% of all cervical cancers, represents a major breakthrough for women’s health. In the last year alone, Merck’s Gardasil has been approved in 76 countries worldwide, including the United States. GlaxoSmithKline’s Cervarix,...

Human Papillomavirus (HPV) is the most common sexually transmitted disease which can infect different parts of the body including uterus. Cervical cancer is the second most common cancer among women worldwide. In 2008, Zur Hausen received the Nobel Prize in “Medicine or Physiology” for proving the causative link between HPV and cervical cancer research. The HPV-related disease appears to be inc...

A common sexually transmitted infection, human papillomavirus (HPV) has been linked to the development of cervical, anogenital, and head and neck cancers and genital warts. (2) Several randomized controlled trials have explored the efficacy and safety of two vaccines for primary prevention of infection by HPV types 16 and 18, those most commonly implicated in the development of cervical cancer....